tnp-470
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00000763)
Timeline
Indications
Mechanism of action
- Methionine aminopeptidase 2INHIBITOR
METAP2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2,5)oct-6-yl(chloroacetyl) carbamate
- agm 1470
- agm-1470
- caplostatin
- o-chloroacetylcarbamoylfumagillol
- o-chloroacetylcarbamoylfumagillol
- o-(chloroacetylcarbamoyl)fumagillol
- o-(chloroacetylcarbamoyl)fumagillol
- o-(chloroacetylcarbamoyl)fumagillol
- tnp 470
- tnp-470
- tnp-470
- tnp-470
- tnp-470
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00038701 | Phase 2 | Aug 1, 2000 | University of Texas at Houston |
| NCT00000763 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 1999 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2000 |
2 organizations
Page 1 / 1